Metabolic Syndrome, Cardiovascular Disease, and Mitochondrial Function: Molecular Replacement and Antioxidant Supplements to Prevent Membrane Oxidation and Restore Mitochondrial Function

Garth L. Nicolson, Department of Molecular Pathology,
The Institute for Molecular Medicine, 16371 Gothard St. H, Huntington Beach,
California 92647, USA


One of the central defects in metabolic syndrome (MS) and its associated diseases (type-2 diabetes, vascular inflammation, atherosclerosis, among other diseases) as well as fatiguing illnesses is excess cellular oxidative stress. Oxidative stress affects many organ systems, including pancreatic beta cells, nerve cells, immune cells, and it generally affects the vascular system. Oxidative damage to membranes results in reduced efficiency of the mitochondrial electron transport chain, the main source of energy in our cells. Recent evidence indicates that reduced mitochondrial function caused by membrane oxidation is related to fatigue, a complaint in MS and cardiovascular disease (CVD) and the major complaint in fatiguing illnesses. Lipid replacement therapy administered as a nutritional supplement with antioxidants can prevent excess oxidative membrane damage, restore mitochondrial membrane function, and reduce fatigue in a variety of clinical conditions.

Introduction—Metabolic Syndrome

Metabolic syndrome (MS), estimated in over 22% of the U.S. population, is made up of several interrelated disturbances of glucose and lipid metabolism [1]. The major risk factors for MS are: abdominal obesity, hyperglycemia, lipid dysfunction (increased triacylglyerols, increased levels of small and dense low-density lipoproteins and reduced levels of high-density lipoproteins), elevated blood pressure, and the presence of prothrombotic and proinflammatory states [2,3].

            Insulin resistance is one of the initial signs in the development of MS [4]. Insulin secreted by the pancreatic?beta cells in response to increased circulating levels of glucose and amino acids is essential for development, growth, and maintenance of glucose homeostasis [5]. When the circulating concentrations of insulin are insufficient to regulate the above processes, insulin resistance occurs. Insulin resistance is one of the primary events in the development of MS, and it is thought to induce the clinical sequelae that we know as MS [1].

Defects in the capacity to metabolize fatty acids and glucose are thought to play an important role in insulin resistance and MS [6]. Accumulations of glycerols and free fatty acids in non-adipose tissues correlate strongly with insulin resistance [7,8]. Gene expression modifications in adipose tissue are thought to be responsible for enhanced secretion of MS-related factors [9], and in muscle tissue decreased oxidative capacity and fat accumulation may also induce skeletal muscle insulin resistance [6].

Mitochondrial Damage and Type 2 Diabetes

Various studies point to generalized mitochondrial dysfunction in MS and reduction in electron transport chain activity in type 2 diabetes patients along with fatigue [6,10,11]. Mitochondrial dysfunction has been linked to chronic insulin resistance, which results in preferential metabolism of fatty acids, reducing glucose utilization [12]. This causes gradual pancreatic beta and other cell dysfunction due to fatty acid-stimulated changes in mitochondrial proteins, resulting in an uncoupling of mitochondrial respiration, reduced electron transport chain activity and energy production, and increased production of reactive oxygen species (ROS) [6,13-15]. This results in membrane damage and fatigue [13].

            When mitochondria function properly, the amount of superoxide produced as a consequence of electron transport activity is effectively neutralized by endogenous antioxidants and antioxidant enzymes [16]. In MS and associated diseases excess ROS is produced [6,14,15]. Fatty acids are particularly sensitive to ROS oxidation, resulting in the formation of lipid peroxides, which are toxic and lead to free-radical damage, especially in MS and type 2 diabetics [16-18]. In obese, insulin-resistant, pre-diabetic subjects higher amounts of free fatty acids (and their peroxide derivatives) have been found [19]. These are subject to peroxidative events that result in damage to mitochondrial components. Even before the diagnosis of MS or type 2 diabetes, the accumulation of oxidized fatty acids in mitochondria can result in progressive damage. For example, in elderly subjects oxidized fatty acids accumulate in muscle mitochondria, and this is related to mitochondrial dysfunction [20].

            Type 2 diabetes is thought to occur as a consequence of persistent hyperglycemia [18], which causes: (a) formation of advanced glycation end products (AGEs, the products of nonenzymatic glycation and oxidation), their oxidation, and interactions with cell receptors and cellular accumulation; (b) activation of various forms of protein kinase C; (c) induction of the polyol pathway; and (d) increased hexosamine pathway flux [21-26]. These pathways are associated with elevated oxidative stress and over-production of superoxide (and thus ROS/RNS), but the link between hyperglycemia and increased mitochondrial superoxide production may not be mediated solely by the redox state of electron carriers [18].

Metabolic Syndrome, Atherosclerosis and Coronary Heart Disease

Atherosclerosis involves chronic inflammatory damage to blood vessels, due to lipid accumulation, inflammatory response, vessel cell death, and thrombosis, which can eventually result in the occlusion of heart and other tissue blood vessels. A main cause of CVD and stroke, atherosclerosis is characterized by a number of risk factors, including abnormalities in lipoprotein subclass distribution, increases in vascular acute phase response proteins, changes in vascular endothelial cell adhesion molecules and certain cytokines [24]. In the cardiovascular system ROS play an essential physiological role in maintaining vascular integrity, and when they are in excess they play a pathological role in cardiovascular dysfunction [25,26].

The process of atherosclerosis is thought to begin with abnormalities in lipoprotein subclasses, such as triglyceride-rich lipoproteins, their remnants, and smaller, denser low-density lipoproteins, hallmarks of MS [27]. In MS these proinflammatory lipoproteins and their remnants are susceptible to oxidation [28], and the presence of the oxidized lipoprotein subclasses is significantly associated with an abundance of macrophages in atherosclerotic lesions [29].

When they interact with the blood vessel wall, the oxidized lipoprotein subclasses are proinflammatory and can induce endothelial adhesion molecules, which attract monocytes [30,31]. The adhesion and movement of adherent monocytes to subendothelial layers and their differentiation into inflammatory, ROS-producing macrophages is associated with atherosclerotic plaques. The unstable plaques can break off and form thrombi that can occlude blood vessels in the heart, resulting in myocardial infarction, ischemia, and heart failure.

Another association between MS and chronic inflammation in the cardiovascular system is the elevation of C-reactive protein (CRP) [32,33]. In MS the presence of C-reactive protein is one of the best predictors for future CVD and type 2 diabetes [34,35].

Mitochondria in Aging and Fatigue

Fatigue or lack of energy occurs naturally during aging and is a common condition in many clinical diagnoses, including MS, type 2 diabetes, CVD, respiratory, musculoskeletal, and bowel conditions as well as infections and cancer [36]. The phenomenon of fatigue has been defined as a multidimensional sensation, and recently attempts have been made to determine its extent and possible causes [37]. Fatigue is related to reductions in the efficiency of mitochondrial energy systems, and oxidative damage to mitochondrial components can impair oxidative phosphorylation and cause fatigue [36]. Mitochondria are critical elements in the process of aging, and they have been proposed to be the regulators of cellular life span [38]. During aging and fatigue antioxidant enzymes, low molecular weight antioxidants and enzyme repair mechanisms along with biosynthesis cannot restore or replace enough of the ROS-damaged molecules to maintain mitochondrial function [39,40]. Disease and infection can also result in excess oxidative damage that exceeds the abilities of cellular systems to repair and replace damaged molecules [39-41].


Use of Antioxidants to Prevent Excess Oxidative and Mitochondrial Damage

Preventing damage to cellular and mitochondrial membranes is important in preventing loss of electron transport function and cellular energy in MS and other chronic conditions [42]. This can be accomplished, in part, by neutralizing excess ROS with various types of antioxidants or increasing free-radical scavenging systems [18,42,43]. In MS and associated diseases dietary supplementation has been used with low molecular weight antioxidants, some accessory molecules, such as the metal ion cofactors zinc, manganese, copper, vanadium, chromium, and selenium, and certain vitamins with some antioxidant properties (C, E, A, CoQ10) [18,36,44-46]. In addition to trace metal ions and vitamins, there are at least 40 micronutrients required in the human diet [47], and aging increases the need to supplement these to prevent age-associated damage. Such supplementation, however, may not be sufficient to maintain cellular components free of oxidative damage [36,48,49], and antioxidants alone cannot replace damaged cellular components [36,50].

In MS-associated diseases dietary antioxidants, trace metal ions and vitamins have been proposed (separately or together) to alter the course of MS progression and inhibit the progression of MS-associated diseases [18,43]. In most of these cases the effects of antioxidants and other supplements were measured by changes in blood markers [2,46]. For example, vitamin C has been shown to improve endothelial-dependent vasodilation in MS and type 2 diabetes [51,52], and excess vitamin C in combination with vitamin E may reduce the overall risk of CVD [53]. However, despite the evidence for a link between excess oxidative stress in MS and associated diseases, a direct link between the intake of antioxidant nutrients, even in high concentrations, and the ability to prevent or delay MS disease progression has not been proven [48,54,55]. For example, in the antioxidant prevention of CVD or its complications only one-half (4/8) of the published clinical studies reviewed by Paolisso et al. [53] showed positive results in terms of reducing markers associated with heart disease. In type 2 diabetes patients antioxidant supplementation reduced blood glucose or other markers of diabetes in five of seven studies examined [55]. The variations in results were explained by differences in the design of the studies, differences in supplement dose(s), and duration of the trials as well as the criteria for beneficial results. Often follow-on randomized, controlled clinical trials failed to show any significant benefit of antioxidants [56].

Mixtures of antioxidants, vitamins, trace minerals, and herbal extracts may be more effective in preventing early stage progression of MS [42]. Even in late stage diseases like type 2 diabetes and CHD, mixtures of antioxidants and minerals were useful in controlling some signs, such as blood pressure [46,57]. Blinded, controlled studies on antioxidant-vitamin-mineral-herbal products like the Akesis supplement (Akesis Scientific Inc.) have yet to be published, but preliminary studies indicate that such supplements may be beneficial in type 2 diabetes patients as measured by glycemic control or decreases in circulating oxidant markers [42]. A newer version of this supplement mixture (InResponse®, Response Micronutrients Inc.) has shown good results in animal studies [55]. However, long-term studies will be necessary to see if nutritional antioxidant mixtures affect MS disease progression and the development of MS-associated diseases.


Replacement of Damaged Mitochondrial Membrane Components by Lipid Replacement Therapy

Lipid replacement therapy (LRT) plus antioxidants has been used to reverse oxidative damage and increase mitochondrial function in certain clinical disorders involving loss of mitochondrial function [50,58,59]. LRT should be useful for MS patients, because it replaces damaged lipids with undamaged lipids to ensure proper structure and function of cellular and mitochondrial membranes. It is usually combined with antioxidants, vitamins and minerals to provide additional antioxidant protection [58,59]. LRT plus antioxidants has proven to be an effective method to prevent ROS-associated changes in mitochondrial function [50,58,59]. As discussed above, antioxidants alone may not completely eliminate or reverse ROS damage, and this is why LRT is an important addition to antioxidant dietary supplementation [42,43]. One LRT supplement, NTFactor® (Nutritional Therapeutics Inc.), has been used successfully in animal and clinical studies [50,58-60]. NTFactor's encapsulated lipids are protected from oxidation in the gut and can be absorbed and transported into tissues without significant oxidative damage [50,58].

In clinical studies LRT has been used to reduce fatigue and protect mitochondrial membranes [36,58-60]. Propax (Nutritional Therapeutics Inc.), a dietary supplement containing NTFactor along with vitamins, minerals, and other nutrients, has been used in severely chronic fatigued patients, and it was found to reduce their fatigue approximately 40% within 8 weeks [59]. NTFactor in moderately and severely fatigued subjects was found to increase mitochondrial function and improve fatigue scores. For example, in patients with chronic fatigue there was a 35.5% reduction in fatigue (P < 0.001) with a proportionate increase in mitochondrial function [59,60]. The results indicated that in moderately to severely fatigued subjects dietary LRT plus antioxidants can significantly improve and even restore mitochondrial function and significantly improve fatigue scores. Similar findings with LRT and antioxidants have been observed in CFS and fibromyalgia syndrome patients [60]. The advantage of LRT plus antioxidants over antioxidant mixtures alone is that further oxidative damage is reduced and damaged (oxidized) lipid components are gradually replaced, restoring function to cellular membranes.


  1.    Fonseca VA. The metabolic syndrome, hyperlipidemia and insulin resistance. Clin Cornerstone 2005;7:61-72.
  2.    Houston MC, Egan BM. The metabolic syndrome. Pathophysiology, diagnosis, clinical aspects, prevention and nonpharmacologic treatment: emphasis on lifestyle modifications, nutrition, nutritional supplements, vitamins, minerals, antioxidants, weight management and exercise. J Am Nutraceutical Assoc 2005;8(2):3-83.
  3.    Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr 2006;83:1248-51.
  4.    Einhorn D. ACE position statement on insulin resistance syndrome. Endocrinol Pract 2003;9:237-52.
  5.    Chakraborty C. Biochemical and molecular basis of insulin resistance. Curr Protein Peptide Sci 2006;7:113-31.
  6.    Schrauwen P, Hesselink MKC. Oxidative capacity, lipotoxicity and mitochondrial damage in type 2 diabetes. Diabetes 2004;53:1412-17.
  7.    Krssak M, Falk Petersen K, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR study. Diabetologica 1999;42:113-16.
  8.    Perseghin G, Scifo P, De Cobelli F, et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999;48:1600-1606.
  9.    Itani SI, Ruderman NB, Schmieder F, et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C and IkappaB-alpha. Diabetes 2002;51:2005-11.
  10.    Kelly DE, He J, Menshikova EV, et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002;51:2944-50.
  11.    Drivsholm T, de Fine Olivarius N, Nielsen AB, Siersma V. Symptoms, signs and complications in newly diagnosed type 2 diabetic patients, and their relationship to glycaemia, blood pressure and weight. Diabetologica 2005;48:210-14.
  12.    Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 2003;27:S6-S11.
  13.    Hagen T, Vidal-Puig A. Mitochondrial uncoupling proteins in human physiology and disease. Minerva Med 2002;93:41-57.
  14.    Schrauwen P, Hesselink MK, Blaak EE, et al. Uncoupling protein 3 content is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2001;50:2870-73.
  15.    Schrauwen P. Skeletal muscle uncoupling protein 3 (UCP3): mitochondrial uncoupling protein in search of a function. Curr Opin Clin Nutr Metab Care 2002;5:265-70.
  16.    Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003;552:335-44.
  17.    Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990;87:1620-24.
  18.    Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004;53(Suppl 1):S110-S118.
  19.    Russell AP, Gastaldi G, Bobbioni-Harsch E, et al. Increased uncoupling protein 3 content does not affect mitochondrial function in human skeletal muscle in vivo. J Clin Invest 2003;111:479-86.
  20.    Peterson KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003;300:1140-42.
  21.    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
  22.    Rosen P, Nawroth PP, King G, et al. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001;17:189-212.
  23.    Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003;26:1589-96.
  24.    Zambon A, Pauletto P, Crepaldi G. The metabolic syndrome-a chronic cardiovascular inflammatory condition. Aliment Pharmacol Ther 2005;22(Suppl.2):20-23.
  25.    Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Artioscler Thromb Vasc Biol 2000;20:2175-83.
  26.    Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004;122:339-52.
  27.    Berliner JA, Watson AD. A role for oxidized phospholipids in artherosclerosis. N Eng J Med 2005;353:9-11.
  28.    Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoportiens to oxidative modification in subjects with the artherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-56.
  29.    Faggin E, Zambon A, Pauto M, et al. Association between the 514C-T polymorphism of hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis. J Am Coll Cardiol 2002;40:1059-66.
  30.    Colome C, Martinez-Gonsalez J, Vidal F, et al. Small oxidative changes in atherogenic LDL concentration irreversibly regulate adhesiveness of human endothelial cells: effect of the lazaroid U74500A. Atherosclerosis 2000;149:295-302.
  31.    Doi H, Kugiyama K, Oka H, et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000;102:670-76.
  32.    Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.
  33.    Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen and leukocyte count: finding from the third national health and nutrition examination survey. Atherosclerosis 2003;168:351-58.
  34.    Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
  35.    Ndumele CE, Pradhan AD, Ridker PM. Interrelationships between inflammation, C-reactive protein and insulin resistance. J Cardiometabolic Syndr 2006;1:190-96.
  36.    Nicolson GL. Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane oxidation and restore mitochondrial function. J Cell Biochem 2007;100: in press.
  37.    Kroenke K, Wood DR, Mangelsdorff AD, et al. Chronic fatigue in primary care: prevalence, patient characteristics, and outcome. JAMA 1988;260:929-34.
  38.    Xu D, Finkel T. A role for mitochondria as potential regulators of cellular life span. Biochem Biophys Res Commun 2002;294:245-48.
  39.    Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;2:298-300.
  40.    Huang H, Manton KG. The role of oxidative damage in mitochondria during aging: a review. Front Biosci 2004;9:1100-17.
  41.    Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001;18:685-716.
  42.    Opara EC. Oxidative stress, micronutrients, diabetes mellitus and its complications. J Royal Soc Health 2002;122:28-34.
  43.    Machlin IJ, Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. FASEB J 1987;1:441-45.
  44.    Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev 2001;6:450-59.
  45.    Miquel J. Can antioxidant diet supplementation protect against age-related mitochondrial damage? Ann NY Acad Sci 2002;959:317-47.
  46.    Houston MC. Nutraceuticals, vitamins antioxidants and minerals in the prevention and treatment of hypertension. Prog Cardiovasc Dis 2005;47:396-449.
  47.    Ames BM. Micronutrients prevent cancer and delay aging. Toxicol Lett 1998;102:1035-38.
  48.    Granot E, Kohen R. Oxidative stress in childhood-in health and disease states. Clin Nutr 2003;23:3-11.
  49.    Hsueh WA, Quiñones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003;92(Suppl 4A):10J-17J.
  50.    Nicolson GL. Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function. Pathol Oncol Res 2005;11:139-44.
  51.    Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasoldilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-28.
  52.    Ting HH, Timimi FK, Haley EA, et al. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997;95:2617-22.
  53.    Paolisso G, Esposito R, D'Alessio MA, Barbieri M. Primary and secondary prevention of arterosclerosis: is there a role for antioxidants? Diabetes Metab 1999;25:298-306.
  54.    Leppala JM, Virtamo J, Fogelholm R, et al. Control trial of alpha-tocopheraol and beta carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol 2000;20:230-35.
  55.    Opara EC. Role of oxidative stress in the etiology of type 2 diabetes and the effect of antioxidant supplementation on glycemic control. J Investig Med 2004;52:19-23.
  56.    Ueda S, Yasunari K. What we learned from randomized clinical trials and cohort studies of antioxidant vitamins. Focus on vitamin E and cardiovascular disease. Curr Pharm Biotechnol 2006;7:69-72.
  57.    Farvid MS, Jalali M, Siassi F, et al. The impact of vitamins and/or mineral supplementation on blood pressure in type 2 diabetes. J Am Coll Nutr 2004;23:272-79.
  58.    Nicolson GL. Lipid replacement as an adjunct to therapy for chronic fatigue, anti-aging and restoration of mitochondrial function. J Am Nutraceutical Assoc 2003;6(3):22-28.
  59.    Ellithorpe RR, Settineri R, Nicolson GL. Reduction of fatigue by use of a dietary supplement containing glycophospholipids. J Am Nutraceut Assoc 2003;6(1):23-28.
  60.    Nicolson GL, Ellithrope R. Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. J Chronic Fatigue Syndr 2006;13(1):57-68.